Top Biomedical Science(@imedverse) 's Twitter Profileg
Top Biomedical Science

@imedverse

Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News

ID:1886086740

calendar_today20-09-2013 10:38:31

12,7K Tweets

78,2K Followers

4,7K Following

Follow People
Nature Reviews Drug Discovery(@NatRevDrugDisc) 's Twitter Profile Photo

Glue-based KRAS inhibitors make their debut cancer trial mark bit.ly/3M8zJNJ
Revolution Medicines’ macrocyclic KRAS inhibitors RMC-6236 and RMC-6291 have notched up encouraging phase I data in various cancers
More on macrocycles as drugs bit.ly/3Pf0i4B

Glue-based KRAS inhibitors make their debut cancer trial mark bit.ly/3M8zJNJ Revolution Medicines’ macrocyclic KRAS inhibitors RMC-6236 and RMC-6291 have notched up encouraging phase I data in various cancers #ESMO More on macrocycles as drugs bit.ly/3Pf0i4B
account_circle
Benedetta Conte(@BenedettaConte5) 's Twitter Profile Photo

Terrific session at on early TNBC led by four giants of TNBC research.

It is clear that we need to integrate biomarkers already, to finally select patients for proper tp escalation and de-escalation.

Congrats Aleix Prat #PrecisionOncology Rebecca Dent V.Guarneri P. Schmid

Terrific session at #ESMO2023 on early TNBC led by four giants of TNBC research. It is clear that we need to integrate biomarkers already, to finally select patients for proper tp escalation and de-escalation. Congrats @prat_aleix @RebeccaDSing V.Guarneri P. Schmid
account_circle
Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo


4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR.
5️⃣ ct DNA HIGH CONCORDANCE.
6️⃣ VISION: we need a lot to do. Personalized Therapy.
7️⃣ PSMA intensity could be predictive.
silke gillessen Advanced Prostate Cancer Consensus Conference OncoAlert

#ESMO2023 4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR. 5️⃣ ct DNA HIGH CONCORDANCE. 6️⃣ VISION: we need a lot to do. Personalized Therapy. 7️⃣ PSMA intensity could be predictive. @Silke_Gillessen @APCCC_Lugano @OncoAlert
account_circle
Dipesh Uprety MD FACP(@DipeshUpretyMD) 's Twitter Profile Photo

CheckMate-816
Pts with resectable IB (≥4 cm) -IIIA NSCLC randomized to Nivo plus Ipi vs Chemo (exploratory analysis)
➡️74% vs 76% underwent definitive surgery
➡️Md EFS was 54.8 vs 20.9 (HR 0.77)
➡️Higer MRP and pCR in IO arm
OncoAlert The Cancer News

CheckMate-816 #ESMO23 Pts with resectable IB (≥4 cm) -IIIA NSCLC randomized to Nivo plus Ipi vs Chemo (exploratory analysis) ➡️74% vs 76% underwent definitive surgery ➡️Md EFS was 54.8 vs 20.9 (HR 0.77) ➡️Higer MRP and pCR in IO arm #LCSM @OncoAlert @BTFCancerNews #ESMO2023
account_circle
Rana McKay(@DrRanaMcKay) 's Twitter Profile Photo

The one and only ⁦Laurence Albiges⁩ presenting Litespark-005. Practice changing study! With impressive ORR and tail on the PFS curve. Censoring in control could explain crossing of curves.

The one and only ⁦@AlbigesL⁩ presenting Litespark-005. Practice changing study! With impressive ORR and tail on the PFS curve. Censoring in control could explain crossing of curves. #esmo2023
account_circle
Shannon Westin(@ShannonWestin) 's Twitter Profile Photo

GY004 explored olaparib vs cedirinib/olaparib vs platinum-based chemotherapy in platinum sensitive
👎No difference in progression free or overall survival
🧐High number of withdrawals in the SOC arm may have impacted these results....

GY004 explored olaparib vs cedirinib/olaparib vs platinum-based chemotherapy in platinum sensitive #OvarianCancer 👎No difference in progression free or overall survival 🧐High number of withdrawals in the SOC arm may have impacted these results.... #ESMO2023 #gyncsm
account_circle
Lodovica Zullo(@LodovicaZullo) 's Twitter Profile Photo

1456P NSCLC metastatic. While waiting for RCT results (PERSEE), some 'good prognosis' patients might benefit from Pembro alone.
Retrospective analysis of more than 400 pts from 3 European facilities.
Primary outcome/endpoint: survival/OS.
ESMO - Eur. Oncology

1456P NSCLC metastatic. While waiting for RCT results (PERSEE), some 'good prognosis' patients might benefit from Pembro alone. Retrospective analysis of more than 400 pts from 3 European facilities. Primary outcome/endpoint: survival/OS. @myESMO #ESMO2023
account_circle
Shannon Westin(@ShannonWestin) 's Twitter Profile Photo

🧐PFS and OS by TCGA classifiers was quite intriguing
🌟POLE does well no matter what
🌟MMRd improved survival with IO (as expected)
🌟p53m improved survival with IO (not what I would expect!!!)

🧐PFS and OS by TCGA classifiers was quite intriguing 🌟POLE does well no matter what 🌟MMRd improved survival with IO (as expected) 🌟p53m improved survival with IO (not what I would expect!!!) #EndometrialCancer #gyncsm #ESMO2023 #ImmunoOnc
account_circle
Gustavo(@gusviani) 's Twitter Profile Photo

🎙️SACTION trial shows a high major path response & pCR rates in CS II/III without EGFR mut w/ neoadjuvant SBRT24 Gy /3 daily Fr ➡️ immunochemo ➡️🔪❗️OncoAlert
👉 MPR 76%
👉pCR 52%
👉ypN0 76%

🎙️SACTION trial shows a high major path response & pCR rates in CS II/III #NSCLC without EGFR mut w/ neoadjuvant SBRT24 Gy /3 daily Fr ➡️ immunochemo ➡️🔪❗️@OncoAlert #ESMO2023 👉 MPR 76% 👉pCR 52% 👉ypN0 76%
account_circle
Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo


4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR.
5️⃣ ct DNA HIGH CONCORDANCE.
6️⃣ VISION: we need a lot to do. Personalized Therapy.
7️⃣ PSMA intensity could be predictive.
silke gillessen Advanced Prostate Cancer Consensus Conference OncoAlert

#ESMO2023 4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR. 5️⃣ ct DNA HIGH CONCORDANCE. 6️⃣ VISION: we need a lot to do. Personalized Therapy. 7️⃣ PSMA intensity could be predictive. @Silke_Gillessen @APCCC_Lugano @OncoAlert
account_circle
Markus Eckstein(@Markuseckstein3) 's Twitter Profile Photo

🔥Breaking News at !🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution . Terrific presentation by Tom Powles. 🙌🔬🎗️ UroToday.com OncoAlert ESMO - Eur. Oncology

🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by @tompowles1. 🙌🔬🎗️ @urotoday @OncoAlert @myESMO
account_circle
d.planchard(@dplanchard) 's Twitter Profile Photo

Congratulations Nicolas Girard for this new standard of care for our EGFRex20ins NSCLC patients, a great step forward. Need to manage the skin tox with amivantamab ESMO - Eur. Oncology

Congratulations @nicogirardcurie for this new standard of care for our EGFRex20ins NSCLC patients, a great step forward. Need to manage the skin tox with amivantamab @myESMO #ESMO2023
account_circle
Shannon Westin(@ShannonWestin) 's Twitter Profile Photo

👏Camrelizumab (anti-PD1) + famitinib (TKI) has improved response rate (42.9%) vs camrelizumab alone (22%) or chemotherapy (14.3%) in recurrent - extremely intriguing data that will need larger study

👏Camrelizumab (anti-PD1) + famitinib (TKI) has improved response rate (42.9%) vs camrelizumab alone (22%) or chemotherapy (14.3%) in recurrent #CervicalCancer - extremely intriguing data that will need larger study #ESMO2023 #gyncsm #ImmunoOnc
account_circle
Rana McKay(@DrRanaMcKay) 's Twitter Profile Photo

Data from PSMAFore presented by Dr. Sartor. Activity prior to chemotherapy. Crossover likely colored OS. Does not answer when to give but has activity pre and post taxane.

Data from PSMAFore presented by Dr. Sartor. Activity prior to chemotherapy. Crossover likely colored OS. Does not answer when to give but has activity pre and post taxane. #ESMO2023
account_circle
Stefano Arcangeli(@StAr_MCM74) 's Twitter Profile Photo

🆕 insights from the STAMPEDE trial presented :
5️⃣-year incidence of upper urinary tract obstruction significantly ⬇️ with prostate RT in all men with mHSPC❗️

Chris Parker Nick James ESMO - Eur. Oncology OncoAlert ESTRO ASTRO

🆕 insights from the STAMPEDE trial presented #ESMO2023: 5️⃣-year incidence of upper urinary tract obstruction significantly ⬇️ with prostate RT in all men with mHSPC❗️ #ProstateCancer @PCaParker @Prof_Nick_James @myESMO @OncoAlert @ESTRO_RT @ASTRO_org
account_circle